Compare ARVN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | DRUG |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 707.1M |
| IPO Year | 2018 | 2020 |
| Metric | ARVN | DRUG |
|---|---|---|
| Price | $10.92 | $87.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 6 |
| Target Price | $15.05 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 781.8K | 144.0K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.90 | $23.18 |
| 52 Week High | $14.22 | $123.75 |
| Indicator | ARVN | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 63.01 |
| Support Level | $9.02 | $69.83 |
| Resistance Level | $12.43 | $91.00 |
| Average True Range (ATR) | 0.63 | 5.25 |
| MACD | 0.07 | 1.89 |
| Stochastic Oscillator | 44.71 | 87.13 |
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.